The Impact of Modern Chemotherapy and Chemotherapy-Associated Liver Injuries (CALI) on Liver Function: Value of 99mTc-Labelled-Mebrofenin SPECT-Hepatobiliary Scintigraphy.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
18
11
2019
accepted:
16
04
2020
pubmed:
25
8
2020
medline:
15
5
2021
entrez:
25
8
2020
Statut:
ppublish
Résumé
Chemotherapy is increasingly used before hepatic resection, with controversial impact regarding liver function. This study aimed to assess the capacity of 99mTc-labelled-mebrofenin SPECT-hepatobiliary scintigraphy (HBS) to predict liver dysfunction due to chemotherapy and/or chemotherapeutic-associated liver injuries (CALI), such as sinusoidal obstruction syndrome (SOS) and nonalcoholic steatohepatitis (NASH) activity score (NAS). From 2011 to 2015, all consecutive noncirrhotic patients scheduled for a major hepatectomy (≥ 3 segments) gave informed consent for preoperative SPECT-HBS allowing measurements of segmental liver function. As primary endpoint, HBS results were compared between patients with versus without (1) preoperative chemotherapy (≤ 3 months); and (2) CALI, mainly steatosis, NAS (Kleiner), or SOS (Rubbia-Brandt). Secondary endpoints were (1) other factors impairing function; and (2) impact of chemotherapy, and/or CALI on hepatocyte isolation outcome via liver tissues. Among 115 patients, 55 (47.8%) received chemotherapy. Sixteen developed SOS and 35 NAS, with worse postoperative outcome. Overall, chemotherapy had no impact on liver function, except above 12 cycles. In patients with CALI, a steatosis ≥ 30% significantly compromised function, as well as NAS, especially grades 2-5. Conversely, SOS had no impact, although subjected to very low patients number with severe SOS. Other factors impairing function were diabetes, overweight/obesity, or fibrosis. Similarly, chemotherapy in 73 of 164 patients had no effect on hepatocytes isolation outcome; regarding CALI, steatosis ≥ 30% and NAS impaired the yield and/or viability of hepatocytes, but not SOS. In this first large, prospective study, HBS appeared to be a valuable tool to select heavily treated patients at risk of liver dysfunction through steatosis or NAS.
Sections du résumé
BACKGROUND
BACKGROUND
Chemotherapy is increasingly used before hepatic resection, with controversial impact regarding liver function. This study aimed to assess the capacity of 99mTc-labelled-mebrofenin SPECT-hepatobiliary scintigraphy (HBS) to predict liver dysfunction due to chemotherapy and/or chemotherapeutic-associated liver injuries (CALI), such as sinusoidal obstruction syndrome (SOS) and nonalcoholic steatohepatitis (NASH) activity score (NAS).
METHODS
METHODS
From 2011 to 2015, all consecutive noncirrhotic patients scheduled for a major hepatectomy (≥ 3 segments) gave informed consent for preoperative SPECT-HBS allowing measurements of segmental liver function. As primary endpoint, HBS results were compared between patients with versus without (1) preoperative chemotherapy (≤ 3 months); and (2) CALI, mainly steatosis, NAS (Kleiner), or SOS (Rubbia-Brandt). Secondary endpoints were (1) other factors impairing function; and (2) impact of chemotherapy, and/or CALI on hepatocyte isolation outcome via liver tissues.
RESULTS
RESULTS
Among 115 patients, 55 (47.8%) received chemotherapy. Sixteen developed SOS and 35 NAS, with worse postoperative outcome. Overall, chemotherapy had no impact on liver function, except above 12 cycles. In patients with CALI, a steatosis ≥ 30% significantly compromised function, as well as NAS, especially grades 2-5. Conversely, SOS had no impact, although subjected to very low patients number with severe SOS. Other factors impairing function were diabetes, overweight/obesity, or fibrosis. Similarly, chemotherapy in 73 of 164 patients had no effect on hepatocytes isolation outcome; regarding CALI, steatosis ≥ 30% and NAS impaired the yield and/or viability of hepatocytes, but not SOS.
CONCLUSIONS
CONCLUSIONS
In this first large, prospective study, HBS appeared to be a valuable tool to select heavily treated patients at risk of liver dysfunction through steatosis or NAS.
Identifiants
pubmed: 32833150
doi: 10.1245/s10434-020-08988-4
pii: 10.1245/s10434-020-08988-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1959-1969Références
Sturesson C, Nilsson J, Eriksson S, Spelt L, Andersson R. Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. HPB. 2013;15:646–52.
pubmed: 23458360
pmcid: 3731588
doi: 10.1111/hpb.12040
Sturesson C, Keussen I, Tranberg KG. Prolonged chemotherapy impairs liver regeneration after portal vein occlusion: an audit of 26 patients. Eur J Surg Oncol. 2010;36:358–64.
pubmed: 20100648
doi: 10.1016/j.ejso.2009.12.001
pmcid: 20100648
Goere D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg. 2006;10:365–70.
pubmed: 16504881
doi: 10.1016/j.gassur.2005.09.001
pmcid: 16504881
Rickenbacher A, DeOliveira ML, Tian Y, Jang JH, Riener M, Graf R, et al. Arguments against toxic effects of chemotherapy on liver injury and regeneration in an experimental model of partial hepatectomy. Liver Int. 2011;31:313–21.
pubmed: 21281431
doi: 10.1111/j.1478-3231.2010.02446.x
pmcid: 21281431
De Graaf W, Bennink RJ, Vetelainen R, van Gulik TM. Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. J Nucl Med. 2010;51:742–52.
pubmed: 20395336
doi: 10.2967/jnumed.109.069435
pmcid: 20395336
Truant S, Oberlin O, Sergent G, Lebuffe G, Gambiez L, Ernst O, et al. Remnant liver volume to body weight ratio ≥ 0.5%: a new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. J Am Coll Surg. 2007;204:22–33.
Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009;250:540–8.
pubmed: 19730239
doi: 10.1097/SLA.0b013e3181b674df
pmcid: 19730239
Krishnamurthy S, Krishnamurthy GT. Technetium-99 m-iminodiacetic acid organic anions: review of biokinetics and clinical application in hepatology. Hepatology. 1989;9:139–53.
pubmed: 2642291
doi: 10.1002/hep.1840090123
pmcid: 2642291
Choti M a, Sitzmann J V, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.
Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96:1037–42.
pubmed: 17353923
pmcid: 2360122
doi: 10.1038/sj.bjc.6603670
Takamoto T, Hashimoto T, Sano K, Maruyama Y, Inoue K, Ogata S, et al. Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis. Ann Surg Oncol. 2010;17:2747–55.
pubmed: 20425145
doi: 10.1245/s10434-010-1074-4
pmcid: 20425145
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
pubmed: 15273542
pmcid: 1360123
doi: 10.1097/01.sla.0000133083.54934.ae
Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, et al. The “50–50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242:824–8.
pubmed: 16327492
pmcid: 1409891
doi: 10.1097/01.sla.0000189131.90876.9e
Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg. 2007;204:854–62.
pubmed: 17481498
doi: 10.1016/j.jamcollsurg.2006.12.032
pmcid: 17481498
Skrzypczyk C, Truant S, Duhamel A, Langlois C, Boleslawski E, Koriche D, et al. Relevance of the ISGLS definition of posthepatectomy liver failure in early prediction of poor outcome after liver resection: study on 680 hepatectomies. Ann Surg. 2014;13:865–70.
doi: 10.1097/SLA.0000000000000944
Ekman M, Fjalling M, Holmberg S, Person H. IODIDA clearance rate: a method for measuring hepatocyte uptake function. Transpl Proc. 1992;24:387–8.
Boleslawski E, Decanter G, Truant S, Bouras AF, Sulaberidze L, Oberlin O, et al. Right hepatectomy with extra-hepatic vascular division prior to transection: intention-to-treat analysis of a standardized policy. HPB. 2012;14:688–99.
pubmed: 22954006
pmcid: 3461376
doi: 10.1111/j.1477-2574.2012.00519.x
Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.
pubmed: 14998849
doi: 10.1093/annonc/mdh095
pmcid: 14998849
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
pubmed: 15915461
doi: 10.1002/hep.20701
pmcid: 15915461
Truant S, Bouras AF, Petrovai G, Buob D, Ernst O, Boleslawski E, et al. Volumetric gain of the liver after major hepatectomy in obese patients: a case-matched study in 84 patients. Ann Surg. 2013;258:696–704.
pubmed: 23979277
doi: 10.1097/SLA.0b013e3182a61a22
pmcid: 23979277
Vondran FW, Katenz E, Schwartlander R, Morgul MH, Raschzok N, Gong X, et al. Isolation of primary human hepatocytes after partial hepatectomy: criteria for identification of the most promising liver specimen. Artif Organs. 2008;32:205–13.
pubmed: 18201288
doi: 10.1111/j.1525-1594.2007.00524.x
pmcid: 18201288
Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol. 1976;13:29–83.
pubmed: 177845
doi: 10.1016/S0091-679X(08)61797-5
pmcid: 177845
Sharanek A, Burban A, Burbank M, Le Guevel R, Li R, Guillouzo A, et al. Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs. Sci Rep. 2016;6:24709.
pubmed: 27169750
pmcid: 4867683
doi: 10.1038/srep24709
Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72. https://doi.org/10.1200/JCO.2005.05.3074 .
doi: 10.1200/JCO.2005.05.3074
pubmed: 16648507
pmcid: 16648507
Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11:860–8.
pubmed: 17492335
doi: 10.1007/s11605-007-0149-4
pmcid: 17492335
Scoggins CR, Campbell ML, Landry CS, Slomiany BA, Woodall CE, McMasters KM, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol. 2009;16:35–41.
pubmed: 18987915
doi: 10.1245/s10434-008-0190-x
pmcid: 18987915
Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.
pubmed: 16371728
pmcid: 1449955
doi: 10.1097/01.sla.0000193603.26265.c3
Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17:2870–6.
pubmed: 20567921
doi: 10.1245/s10434-010-1166-1
pmcid: 20567921
Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009;145:362–71.
pubmed: 19303984
doi: 10.1016/j.surg.2008.12.002
pmcid: 19303984
Vigano L, De Rosa G, Toso C, Andres A, Ferrero A, Roth A, et al. Reversibility of chemotherapy-related liver injury. J Hepatol. 2017;67:84–91.
pubmed: 28284915
doi: 10.1016/j.jhep.2017.02.031
pmcid: 28284915
Millet G, Truant S, Leteurtre E, Hebbar M, Zerbib P, Huet G, et al. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients. Ann Surg. 2012;256:752–5.
doi: 10.1097/SLA.0b013e31827381ca
Pessaux P, Panaro F, Casnedi S, Zeca I, Marzano E, Bachellier P, et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: Preliminary results of a case–control study. Eur J Surg Oncol. 2010;36:575–82.
pubmed: 20452168
doi: 10.1016/j.ejso.2010.04.010
pmcid: 20452168
Russolillo N, Langella S, Perotti S, Lo Tesoriere R, Forchino F, Ferrero A. Preoperative assessment of chemotherapeutic associated liver injury based on indocyanine green retention test. Int J Surg. 2016;31:80–5.
pubmed: 27260311
doi: 10.1016/j.ijsu.2016.05.065
pmcid: 27260311
Wakiya T, Kudo D, Toyoki Y, Ishido K, Kimura N, Narumi S, et al. Evaluation of the usefulness of the indocyanine green clearance test for chemotherapy-associated liver injury in patients with colorectal cancer liver metastasis. Ann Surg Oncol. 2014;21:167–72. https://doi.org/10.1245/s10434-013-3203-3 .
doi: 10.1245/s10434-013-3203-3
pubmed: 23959055
pmcid: 23959055
Narita M, Oussoultzoglou E, Chenard M-P, Fuchshuber P, Rather M, Rosso E, et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol. 2012;19:2230–7. https://doi.org/10.1245/s10434-011-2112-6 .
doi: 10.1245/s10434-011-2112-6
pubmed: 22402811
pmcid: 22402811
Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu M-PP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118–24.
Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983–90.
pubmed: 17075116
doi: 10.1200/JCO.2006.05.8156
pmcid: 17075116
Soubrane O, Brouquet A, Zalinski S, Terris B, Brezault C, Mallet V, et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010;251:454–60.
pubmed: 20160638
doi: 10.1097/SLA.0b013e3181c79403
pmcid: 20160638
Simpson AL, Leal JN, Pugalenthi A, Allen PJ, Dematteo RP, Fong Y, et al. Chemotherapy-induced splenic volume increase is independently associated with major complications after hepatic resection for metastatic colorectal cancer. J Am Coll Surg. 2015;220:271–80.
pubmed: 25617913
doi: 10.1016/j.jamcollsurg.2014.12.008
pmcid: 25617913
Schiffer E, Frossard JL, Rubbia-Brandt L, Mentha G, Pastor CM. Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome. J Surg Oncol. 2009;99:439–46.
pubmed: 19353590
doi: 10.1002/jso.21276
pmcid: 19353590
Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009;8:225–30.
pubmed: 19822514
doi: 10.3816/CCC.2009.n.038
pmcid: 19822514
Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg. 2003;7:1082–8.
pubmed: 14675719
doi: 10.1016/j.gassur.2003.08.005
pmcid: 14675719
Zeiss J, Merrick HW, Savolaine ER, Woldenberg LS, Kim K, Schlembach PJ. Fatty liver change as a result of hepatic artery infusion chemotherapy. Am J Clin Oncol. 1990;13:156–60.
pubmed: 2138409
doi: 10.1097/00000421-199004000-00013
pmcid: 2138409
Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer. 1998;77:2008–11.
pubmed: 9667683
pmcid: 2150330
doi: 10.1038/bjc.1998.333
Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56:430–9.
pubmed: 20459550
doi: 10.1111/j.1365-2559.2010.03511.x
pmcid: 20459550
Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg. 1998;2:292–8.
pubmed: 9841987
doi: 10.1016/S1091-255X(98)80025-5
pmcid: 9841987
Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7:1034–44.
pubmed: 14675713
doi: 10.1016/j.gassur.2003.09.012
pmcid: 14675713
Baumgaertner I, Ratziu V, Vaillant J-C, Hannoun L, Poynard T, André T. [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review]. Bull Cancer. 2010;97:559–69.
pubmed: 20167564
doi: 10.1684/bdc.2010.1049
pmcid: 20167564
Salgado Júnior W, Donadelli CA de M, Dos Santos JS, Nonino CB. Influence of Roux-en-Y gastric bypass on the hepatocellular function and bile flow of obese patients assessed by scintigraphy with DISIDA. Obes Surg. 2016;26:2718–23.
Şen H, Tan YZ, Binnetoğlu E, Aşik M, Güneş F, Erbağ G, et al. Evaluation of liver perfusion in diabetic patients using 99mTc-sestamibi. Wien Klin Wochenschr. 2015;127:19–23.
pubmed: 25234941
doi: 10.1007/s00508-014-0614-5
pmcid: 25234941
Rijzewijk LJ, van der Meer RW, Lubberink M, Lamb HJ, Romijn JA, de Roos A, et al. Liver fat content in type 2 diabetes: relationship with hepatic perfusion and substrate metabolism. Diabetes. 2010;59:2747–54.
pubmed: 20693345
pmcid: 2963532
doi: 10.2337/db09-1201
Kawahara T, Toso C, Douglas DN, Nourbakhsh M, Lewis JT, Tyrrell DL, et al. Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transpl. 2010;16:974–82.
doi: 10.1002/lt.22099
Le Roux F, Herpe Y-E, Bruyer A-S, Duverlie G, Regimbeau J-M. Les résultats de la culture d’hépatocytes primaires humains peuvent-ils être prédictifs des suites opératoires après hépatectomie (Abstract). J Chir (Communication Orale). 2014:A5–35.
Hewes JC, Riddy D, Morris RW, Woodrooffe AJ, Davidson BR, Fuller B. A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy. J Hepatol. 2006;45:263–70.
pubmed: 16635536
doi: 10.1016/j.jhep.2006.02.015
pmcid: 16635536
Zhao J, van Mierlo KMC, Gómez-Ramírez J, Kim H, Pilgrim CHC, Pessaux P, et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017;104:990–1002.
pubmed: 28542731
doi: 10.1002/bjs.10572
pmcid: 28542731
Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. J Am Med Assoc. 1999;282:1659–64.
doi: 10.1001/jama.282.17.1659
Yang SQ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: Implications for nonalcoholic fatty liver disease pathophysiology. Hepatology. 2001;34:694–706.
pubmed: 11584365
doi: 10.1053/jhep.2001.28054
pmcid: 11584365
Teramoto K, Bowers JL, Kruskal JB, Clouse ME. Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. Transplantation. 1993;56:1076–82.
pubmed: 8249103
doi: 10.1097/00007890-199311000-00005
pmcid: 8249103
Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–57.
pubmed: 14647056
doi: 10.1053/jhep.2003.09022
pmcid: 14647056
Allard MA, Sebagh M, Baillie G, Lemoine A, Dartigues P, Faitot F, et al. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Ann Surg Oncol. 2015;22:1925–32. https://doi.org/10.1245/s10434-014-4272-7 .
doi: 10.1245/s10434-014-4272-7
pubmed: 25448804
pmcid: 25448804